Back to Search
Start Over
Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma
- Source :
- Legal Monitor Worldwide. August 3, 2021
- Publication Year :
- 2021
-
Abstract
- (GlobeNewswire) - Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the first [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Legal Monitor Worldwide
- Publication Type :
- News
- Accession number :
- edsgcl.670535220